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OBJECTIVES This report compares long-term percutaneous coronary intervention (PCI) and coronary
artery bypass graft (CABG) survival among post-CABG patients included in the Angina
With Extremely Serious Operative Mortality Evaluation (AWESOME) randomized trial
and prospective registry.
BACKGROUND Repeat CABG surgery is associated with a higher risk of mortality than first-time CABG.
The AWESOME is the first randomized trial comparing CABG with PCI to include
post-CABG patients.
METHODS Over a five-year period (1995 to 2000), patients at 16 hospitals were screened to identify a
cohort of 2,431 individuals who had medically refractory myocardial ischemia and at least one
of five high-risk factors. There were 454 patients in the randomized trial, of whom 142 had
prior CABG. In the physician-directed registry of 1,650 patients, 719 had prior CABG. Of
the 327 patient-choice registry patients, 119 had at least one prior CABG. The CABG and
PCI survivals for the three groups were compared using Kaplan-Meier curves and log-rank
tests.
RESULTS The CABG and PCI three-year survival rates were 73% and 76% respectively for the 142
randomized patients (75 and 67 patients) (log-rankNS). In the physician-directed registry,
155 patients were assigned to reoperation and 357 to PCI (207 received medical therapy);
36-month survivals were 71% and 77% respectively (log-rank  NS). In the patient-choice
registry, 32 patients chose reoperation and 74 chose PCI (13 received medical therapy);
36-month survivals were 65% and 86% respectively (log-rank test p  0.01).
CONCLUSION Percutaneous coronary intervention is preferable to CABG for many post-CABG
patients. (J Am Coll Cardiol 2002;40:1951–4) © 2002 by the American College of
Cardiology Foundation
In the U.S., an estimated 300,000 coronary artery bypass
graft (CABG) surgeries are done yearly at an estimated cost
of $10 billion (1). Because grafts may clot or develop
atherosclerotic lesions, and because coronary artery disease
progresses in other segments of the coronary tree, eventually
patients with prior CABG return with recurrent symptoms
(2). The operative mortality of reoperations is distinctly
higher than the mortality of first-time operations (1).
Reoperative morbidity is also higher than for initial surgery,
and both mortality and morbidity can be even higher in
elderly, unstable patients with additional risk factors (1).
Patients with one or more prior CABG operations are an
increasing number and proportion of the patients with acute
coronary syndromes and stable angina who are being eval-
uated for revascularization (1). The Society for Thoracic
Surgery database of 594,059 CABG operations included
8.6% to 10.4% reoperations per year from 1987 to 1997
(3–6).
Percutaneous coronary intervention (PCI) has been used
to treat medically refractory myocardial ischemia in patients
with prior CABG since the early 1980s (7,8), but even with
the addition of stents, PCI of patients with prior CABG has
been associated with worse outcomes than PCI of patients
without prior CABG (9,10).
Previous randomized trials of CABG versus PCI ex-
cluded patients with prior CABG operations and did not
include stents and other innovations that have changed
revascularization technique (8–12). This study reports the
long-term survival of 760 revascularized patients (142 in the
randomized trial, 512 in the physician-directed registry,
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106 in the patient-choice registry) in the Angina With
Extremely Serious Operative Mortality Evaluation
(AWESOME) randomized trial and registry, who had at
least one prior CABG (13,14).
METHODS
The AWESOME trial was a nationwide, prospective,
multicenter effort designed to compare the long-term sur-
vival of patients with medically refractory myocardial isch-
emia and risk factors for adverse outcome with CABG. The
AWESOME protocol, baseline characteristics of random-
ized patients and registry patients, and three-year outcomes
of both randomized patients and the overall results of the
two registries (physician-directed and patient-choice) have
been reported (13,14). Patients were enrolled at 16
university-affiliated Veterans Affairs Medical Centers over a
five-year period (1995 to 2000).
During enrollment, 2,431 patients met the clinical criteria
for medically refractory myocardial ischemia and had one or
more of the five high-risk clinical factors, including prior
CABG (13,14). All of these patients underwent clinically
indicated coronary angiography, and 980 had one or more
prior open-heart surgeries (CABG or valve replacement or
both). Of the 980, 719 patients were not acceptable for
revascularization to one of the operators and were referred
(physician-directed) for either repeat CABG (n  155),
PCI (n  357), or medical therapy (n  207). Of the
remaining 261 who were acceptable to both operators, 142
accepted random assignment (75 to CABG, 67 to PCI) and
119 chose for themselves (patient-choice) (32 to CABG, 74
to PCI, and 13 to medical only).
Differences in baseline variable frequencies were tested by
chi-square tests for proportions. Long-term survival was
measured by Kaplan-Meier estimates, which were plotted.
The statistical significance of differences between CABG
and PCI survival curves was judged by global log-rank tests.
Differences between CABG and PCI three-year survival
were computed along with z-tests of the differences.
RESULTS
Table 1 displays the baseline characteristics of AWESOME
randomized and registry patients with prior CABG by the
assigned revascularization. The randomized groups were
comparable. The physician-directed registry had a higher
proportion of three-vessel patients directed to CABG and a
larger proportion of former stroke patients directed to PCI.
Both the physician-directed and the patient-choice registry
subgroups show a higher proportion of diabetes among
patients assigned to PCI compared with those assigned
CABG, and the difference for the patient-choice group is
statistically significant. The patient-choice registry assigned
CABG had a higher proportion of patients with a severely
reduced ejection fraction compared with those assigned
PCI; the difference is statistically significant.
Table 2 displays post-CABG patient outcomes. Small
consistent but statistically nonsignificant trends can be
observed for higher PCI rates of revascularization “as
assigned” among the random and registry subgroups and
higher PCI survival at every interval and in every group.
CABG 36-month survival free of recurrent unstable angina
and/or repeat revascularizations is consistently higher than
the PCI value, and the difference is statistically significant in
the physician-directed subgroups. Survival trends free of
Abbreviations and Acronyms
AWESOME  Angina With Extremely Serious
Operative Mortality Evaluation
CABG  coronary artery bypass graft
PCI  percutaneous coronary intervention
Table 1. Baseline Characteristics of Registry Patients With Prior CABG by Revascularization
Baseline
Randomized Physician-Directed Patient-Choice
CABG
(n  75)
PCI
(n  67)
CABG
(n  155)
PCI
(n  357)
CABG
(n  32)
PCI
(n  74)
(%) (%) (%) (%) (%) (%)
Age 70 40 39 36 38 47 45
MI 7 days 12 12 16 17 25 22
LVEF 0.35 15 16 11 17 28 8†
Prior PCI 28 28 23 31 23 24
Diabetes 44 28 28 35 20 38†
Prior stroke 15 11 11 19* 7 7
Hypertension 68 77 70 70 67 68
Smoker 29 26 35 27 22 34
Three-vessel 70 65 71 58† 62 62
TIMI no flow 68 76 72 71 81 66
*Statistically significant difference between CABG and PCI, p  0.05. †Statistically significant difference between CABG and
PCI, p  0.01.
CABG  coronary artery bypass graft; Diabetes  necessitating treatment with insulin and/or oral agents; Hypertension 
persistently elevated blood pressure necessitating treatment; LVEF  left ventricular ejection fraction; MI  myocardial
infarction; PCI  percutaneous coronary intervention; Smoker  current smoker; Three-vessel  all three major epicardial
coronary arteries had at least one 70% lumenal narrowing; TIMI no flow  at least one vessel with Thrombolysis In
Myocardial Infarction grade 0.
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unstable angina or revascularization consistently favor
CABG, and the log-rank tests were statistically different.
Table 3 presents the proportions of patients with various
additional risk factors who were directed by physicians to
PCI (physician-directed registry) or who chose PCI for
themselves (patient-choice registry). Percutaneous coronary
intervention was selected by over a 2:1 ratio in both registry
subgroups (70% were assigned to PCI and 30% to CABG in
both registry subgroups). The PCI assignment frequency
was considerably greater than 50% in all subsets other than
the left ventricular ejection fraction 0.35 in the patient-
choice subgroup.
DISCUSSION
The data reported here extend the conclusion of the
AWESOME randomized trial and registry that PCI is an
alternative to CABG for some patients with medically
refractory myocardial ischemia and high risk of adverse
outcome with CABG, to the subset with prior CABG
(13,14). Additionally, the registry data demonstrate that for
the specific subset of patients with prior CABG surgeries,
both our physicians and patients chose PCI by a 2:1 margin
and among the patient-choice cohort a survival advantage
with PCI was demonstrated.
Numerous single-center and multicenter registries have
documented that CABG carries a higher mortality and
morbidity when it is applied to patients with one or more
prior CABG surgeries than when it is applied to patients
with no prior CABG (1–6). Largely in response to this
need, PCI has been applied to this high-risk cohort (7–10).
Despite the use of stents, the outcome of PCI in patients
with prior CABG has also been worse than PCI among
patients with no prior CABG (8–10).
The 1999 update of the American College of Cardiology/
American Heart Association (ACC/AHA) guidelines for
cardiac surgery emphasizes the high-risk nature of patients
with prior CABG (1). The ACC/AHA guidelines empha-
size the need for trials, which include stents, drugs, and
modern myocardial protection (1). In its review of previous
trials, the guideline emphasizes the following: inadequate
sample sizes, which derive in part from inclusion of only
lower risk patients with inadequate event rates; short follow-
up; and combined end-points which include myocardial
infarction (1). This report addresses these issues and con-
stitutes the only attempt to prospectively randomize patients
with one or more prior heart surgeries between revascular-
ization alternatives.
The primary usefulness of the physician-directed registry
is in documenting what patient characteristics led our
Table 2. CABG and PCI Outcomes of Patients With Prior CABG
Outcomes
Assigned Revascularization
Randomized Physician-Directed Patient-Choice
CABG
(n  75)
PCI
(n  67)
CABG
(n  155)
PCI
(n  357)
CABG
(n  32)
PCI
(n  74)
Revascularized as assigned 96% 100% 92% 96% 94% 97%
Cross-over 10% 2% 2% 2% 3% 3%
In-hospital deaths 6 0 13 2† 5 0†
Short-term survival
1-month 91% 99% 92% 97% 78% 100%
6-month 85% 92% 83% 92% 75% 97%
12-month 81% 89% 79% 88% 72% 95%
36-month survival
Survival 73% 76% 71% 77% 65% 86%†
Survival free of unstable
angina
65% 48% 61% 43%* 62% 43%
Survival free of repeat
revascularizations
65% 55% 60% 50%* 66% 56%
Survival free of unstable
angina or repeat
revascularization
49% 32% 58% 38%* 59% 35%
*Statistically significant difference between CABG and PCI outcomes, p  0.05. †Statistically significant difference between
CABG and PCI outcomes, p  0.01.
Abbreviations as in Table 1.
Table 3. The Percentage Allocation to PCI Among Physician-
Directed and Patient-Choice Patients With Prior CABG
According to Additional Risk Factors at Baseline
High-Risk Subset
Physician-Directed
(n  719)
Patient-Choice
(n  119)
All prior CABG 70% 70%
Prior CABG and
Age 70 71% 69%
AMI 7 days 71% 67%
LVEF 0.35 78% 40%*
Prior PCI 76% 71%
Diabetes 74% 81%*
Prior stroke 80%* 70%
Three-vessel disease 61%* 70%
TIMI no flow 69% 65%
*Statistically significant difference between overall PCI assignment rate and PCI
assignment rate for the particular risk group, p  0.01.
AMI  acute myocardial infarction. Other abbreviations as in Table 1.
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physicians to favor one option or the other. The patient-
choice registry, on the other hand, because it includes
patients who were acceptable to both operators, documents
the factors that influence patients to favor one option or the
other. The findings show that both physicians and patients
preferred PCI by a 2:1 margin. Equally provocative, survival
was uniformly higher with PCI, although statistically sig-
nificant only for the patient-choice registry.
This subset study demonstrates the primary problem
encountered in the AWESOME trial, namely the difficulty
in convincing physicians or patients to permit random
allocation of high-risk cohorts. Despite all the efforts
involved in this nationwide trial, the majority of medically
refractory patients with prior CABG were allocated either
by physician direction or patient choice.
In conclusion, PCI may be the preferred revascularization
strategy for many patients with one or more prior CABG
surgeries.
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